Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

napsr Press Releases

  + XML/RSS  



By NAPSRx
The U.S. Food and Drug Administration has approved Eli Lilly’s Cyramza (ramucirumab) for the treatment of metastatic non-small cell lung cancer (NSCLC) which is the most common type of lung cancer and occurs from cancer cells forming in lung tissue.

By NAPSRx
A new bill has been presented by U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT)  to develop a new pathway for antibiotic drug approvals called the Promise for Antibiotics and Therapeutics for Health (PATH) Act .This act is anticipated to.

By NAPSRx
Eli Lilly will obtain an exclusive worldwide license from Zosano Pharma Corporation to commercialize their investigational therapy ZP-PTH intended to treat osteoporosis patients.

By NAPSRx
AstraZeneca and Eli Lilly and Company have recruited their first patient for the AMARANTH Phase II/III study to assess an oral beta secretase cleaving enzyme (BACE) inhibitor called AZD3293 which is currently being developed as a treatment option for...

By NAPSRx
According to the Decisions Resource Group sales of migraine therapies are projected to grow from $3 billion to over $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan through 2023.

By NAPSRx
AstraZeneca plans to invest up to $200 million to increase manufacturing and production efforts at its biologics manufacturing center in Frederick, Maryland, US.

By NAPSRx
Sanofi and Regeneron’s investigational therapy, Dupilumab has received the Breakthrough Therapy Designation from the U.S.

By NAPSRx
Genzyme’s MS therapy, Lemtrada (alemtuzumab) has been approved by the U.S. Food and Drug Administration to treat patients with relapsing forms of multiple sclerosis (MS).

By NAPSRx
The approval of Pfizer's Trumenba represents the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.

By NAPSRx
Astellas will collaborate with Proteostasis Therapeutics, Inc to develop novel therapeutic contenders that modulate Unfolded Protein Response (UPR) utilizing Proteostasis’ proprietary “Disease Relevant Translation” (DRT™) and “Proteostasis...

By NAPSRx
According to a new study published in the journal Neuropharmacology conducted by research academics at Lancaster University, certain type 2 diabetes drugs on the market have produced neuroprotective effects in a mouse model of Alzheimer's disease.

By NAPSRx
Bristol-Myers Squibb (BMS) has announced their plans to enter into an agreement with F-star Alpha Ltd. giving them the option to obtain the worldwide rights to FS102, a novel Phase 1 ready Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy.

By NAPSRx
In a strategic move to strengthen their vaccine division, Australia’s CSL Ltd will pay Novartis $275 million for their global influenza vaccine business.

By NAPSRx
“The approval of this product provides an important therapeutic option for use in the care of patients with this rare disease,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research.

By NAPSRx
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.

By NAPSRx
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.

By NAPSRx
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.

By NAPSRx
Johnson & Johnson (NYSE: JNJ) has announced their third quarter earnings for 2014 with sales amounting to $18.5 billion, up 5.1% versus the third quarter of 2013.

By NAPSRx
With the worst Ebola outbreak in history, the virus continues to spread and now there's a confirmed case in the United States. It’s no surprise the experimental ZMapp cocktail has been at the center of discussion as the number one treatment option.

By NAPSRx
Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S.  based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement.

All Press Releases

By NAPSRx
The U.S. Food and Drug Administration has approved Xtoro (finafloxacin otic suspension) to treat acute otitis externa commonly referred to as swimmer's ear.

By NAPSRx
The U.S. Food and Drug Administration has approved Eli Lilly’s Cyramza (ramucirumab) for the treatment of metastatic non-small cell lung cancer (NSCLC) which is the most common type of lung cancer and occurs from cancer cells forming in lung tissue.

By NAPSRx
A new bill has been presented by U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT)  to develop a new pathway for antibiotic drug approvals called the Promise for Antibiotics and Therapeutics for Health (PATH) Act .This act is anticipated to.

By NAPSRx
In an attempt to accelerate their presence in the antibiotics market, Merck will acquire Cubist Pharmaceuticals for $102 per share in cash- this transaction is expected to amount to $9.5 billion.

By NAPSRx
Eli Lilly will obtain an exclusive worldwide license from Zosano Pharma Corporation to commercialize their investigational therapy ZP-PTH intended to treat osteoporosis patients.

By NAPSRx
AstraZeneca and Eli Lilly and Company have recruited their first patient for the AMARANTH Phase II/III study to assess an oral beta secretase cleaving enzyme (BACE) inhibitor called AZD3293 which is currently being developed as a treatment option for...

By NAPSRx
According to the Decisions Resource Group sales of migraine therapies are projected to grow from $3 billion to over $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan through 2023.

By NAPSRx
AstraZeneca plans to invest up to $200 million to increase manufacturing and production efforts at its biologics manufacturing center in Frederick, Maryland, US.

By NAPSRx
Sanofi and Regeneron’s investigational therapy, Dupilumab has received the Breakthrough Therapy Designation from the U.S.

By NAPSRx
Genzyme’s MS therapy, Lemtrada (alemtuzumab) has been approved by the U.S. Food and Drug Administration to treat patients with relapsing forms of multiple sclerosis (MS).

By NAPSRx
The approval of Pfizer's Trumenba represents the first vaccine licensed in the United States to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.

By NAPSRx
Astellas will collaborate with Proteostasis Therapeutics, Inc to develop novel therapeutic contenders that modulate Unfolded Protein Response (UPR) utilizing Proteostasis’ proprietary “Disease Relevant Translation” (DRT™) and “Proteostasis...

By NAPSRx
According to a new study published in the journal Neuropharmacology conducted by research academics at Lancaster University, certain type 2 diabetes drugs on the market have produced neuroprotective effects in a mouse model of Alzheimer's disease.

By NAPSRx
Abilify is found to be the preferred brand for the treatment of Schizophrenia according to surveyed U.S. Psychiatrists and Payers

By NAPSRx
Bristol-Myers Squibb (BMS) has announced their plans to enter into an agreement with F-star Alpha Ltd. giving them the option to obtain the worldwide rights to FS102, a novel Phase 1 ready Human Epidermal growth factor Receptor 2 (HER2)-targeted therapy.

By NAPSRx
In a strategic move to strengthen their vaccine division, Australia’s CSL Ltd will pay Novartis $275 million for their global influenza vaccine business.

By NAPSRx
“The approval of this product provides an important therapeutic option for use in the care of patients with this rare disease,” said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research.

By NAPSRx
Celgene Corporation had a remarkable financial third quarter earning a net income of $508 million for 2014 compared to $372 million in 2013.

By NAPSRx
Johnson & Johnson (NYSE: JNJ) will spend $200 million for further expansion on their Ebola vaccine program at Janssen Pharmaceuticals.

By NAPSRx
The Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) to the US Food and Drug Administration (FDA) made a unanimous decision to support the approval of Novartis’ investigational selective interleukin-17A (IL-17A) inhibitor, AIN457...

By NAPSRx
There are many reasons why pharmaceutical sales positions are desired by many aspiring job seekers in the healthcare industry.

By NAPSRx
Roche revealed an impressive financial report for their third quarter with notable sales growth in the pharmaceuticals division.  Group sales were 11.78 billion Swiss francs ( $12.5 billion) up 5% compared to last year.

By NAPSRx
The U.S. Food and Drug Administration has approved two new therapies for the treatment of idiopathic pulmonary fibrosis (IPF) these are Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s  OFEV™ (nintedanib*).

By NAPSRx
Astellas Pharma Inc and an investigator at Harvard Medical will collaborate on discovering the pathologic mechanism and identifying therapeutic treatments for retinitis pigmentosa.

By NAPSRx
Johnson & Johnson (NYSE: JNJ) has announced their third quarter earnings for 2014 with sales amounting to $18.5 billion, up 5.1% versus the third quarter of 2013.

By NAPSRx
The United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for Pfizer's palbociclib. The NDA submitted requests approval of palbociclib, in combination with letrozole.

By NAPSRx
According to the Decisions Resources Group, the chronic heart failure market will grow from approximately $2.9 billion in 2013 to $8.9 billion in 2023.

By NAPSRx
Benralizumab, AstraZeneca’s novel investigational monoclonal antibody to treat patients with severe, uncontrolled asthma and elevated levels of eosinophils (inflammatory white blood cell)  has produced optimistic safety and efficacy clinical data...

By NAPSRx
Chimerix, Inc. (Nasdaq:CMRX), is a biopharmaceutical company focused on developing and commercializing novel, oral antivirals in areas of high unmet medical need.

By NAPSRx
Actavis will acquire Durata’s novel antibiotic DALVANCE - the first and only IV antibiotic approved for the treatment of ABSSSI.

By NAPSRx
Novartis and Bristol-Myers Squibb will join forces on a clinical collaboration which involves evaluating the safety, tolerability and preliminary efficacy of Zykadia(TM), INC280 and EGF816 in combination with Bristol-Myers Squibb's investigational...

By NAPSRx
In an effort to boost research and development for therapies and products to treat rare diseases, the U.S.

By NAPSRx
With the worst Ebola outbreak in history, the virus continues to spread and now there's a confirmed case in the United States. It’s no surprise the experimental ZMapp cocktail has been at the center of discussion as the number one treatment option.

By NAPSRx
Johnson & Johnson (NYSE: JNJ) joins the list of major pharmaceutical giants acquiring smaller biotech/biopharma firms encompassing a growing trend of big pharma’s initiative to further research and development of specific drugs to treat rare...

By NAPSRx
Daiichi Sankyo Company Ltd and Ambit Biosciences, a U.S.  based biopharmaceutical company, have announced their plans to enter into a definitive merger agreement.

By NAPSRx
The U.S Food and Drug Administration (FDA) has approved the inhalation mist version of Boehringer Ingelheim’s Spiriva® Respimat®  (tiotropium bromide) to treat bronchospasm associated with chronic obstructive pulmonary disease (COPD), including...

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) administered as a oral, selective inhibitor of phosphodiesterase 4 (PDE40 to treat  patients with with moderate to severe plaque psoriasis for whom phototherapy or...

By NAPSRx
The FDA’s Fast Track program has been implemented to accelerate the development and review of drugs to treat serious conditions and fill an unmet medical need

By NAPSRx
Baxter and Halozyme have received approval of their subcutaneous treatment, HYQVIA to treat adult patients with primary immunodeficiency (PI).

By NAPSRx
Takeda Pharmaceuticals and Orexigen® Therapeutics, Inc  have announced the FDA  approval of Contrave®  ®(naltrexone HCI and bupropion HCI) extended release tablets to treat obese or overweight adults  with at least one...

By NAPSRx
Novartis heralds breakthrough clinical results with experimental drug to treat heart failure. ‘It’s been at least a decade since we've had a breakthrough of this magnitude,’’ said Dr. Clyde Yancy, cardiology chief at Northwestern University

By NAPSRx
Mylan is an industry leader in the generics and specialty pharmaceuticals market with sales in approximately 140 countries and territories.

By NAPSRx
According to Thomson Reuters, the pharmaceutical industry’s sales will amount to $1 Trillion in 2014.

By NAPSRx
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) has received FDA approval for Ferric Citrate (formerly known as Zerenex) to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

By NAPSRx
Keytruda, developed by Merck is intended for patients with advanced melanoma and who are unresponsive to other therapies.

By NAPSRx
The new life science division of Google called Calico will join forces with Abbvie to collaborate on the discovery, development and commercialization of new therapies in a research deal worth approximately $1.5 billion.

By NAPSRx
Biotech giant Abbvie's collaborative deal with Infinity Pharmaceuticals to develop and market duvelisib is worth approximately $800 million.

By NAPSRx
ELELYSO is the first FDA-approved plant cell-based recombinant therapeutic protein and is currently marketed in the United States by Pfizer Inc.

By NAPSRx
Amgen is dedicated to discovering, developing, manufacturing and delivering innovative human therapeutics for patients with debilitating illnesses.

By NAPSRx
The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Promacta® developed by GlaxoSmithKline (GSK) to treat a rare bone marrow disorder.



Page:

Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share